EGFR is amplified and/or mutated in at least 10–15% of NSCLC (predominantly adenocarcimomas) [3], and those activating alterations predict clinical response to EGFR inhibitors including erlotinib and gefitinib [40]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.